HMGB1: A Promising Therapeutic Approach for Atherosclerosis

Zhixing Fan,Jian Yang,Jun Yang,Chaojun Yang,Xin Guo
DOI: https://doi.org/10.1016/j.ijcard.2015.09.101
IF: 4.039
2016-01-01
International Journal of Cardiology
Abstract:We have read with great interest the recently published article entitled “Inhibition of high-mobility group box 1 improves myocardial fibrosis and dysfunction in diabetic cardiomyopathy” written by Wang, W.K. and his colleagues [ [1] Wang W.K. Wang B. Lu Q.H. et al. Inhibition of high-mobility group box 1 improves myocardial fibrosis and dysfunction in diabetic cardiomyopathy. Int. J. Cardiol. 2014; 172: 202-212 Abstract Full Text Full Text PDF PubMed Scopus (82) Google Scholar ]. This paper indicated that high-mobility group box 1 (HMGB1) inhibition could alleviate cardiac fibrosis and remodeling in diabetic cardiomyopathy. In fact, as a highly conserved, ubiquitous protein in the nuclei and cytoplasm, HMGB1 played a pivotal role in many cardiovascular diseases, such as atherosclerosis, myocardial ischemia/reperfusion injury, heart failure, and myocardial infarction [ [2] Ding H.S. Yang J. High mobility group box-1 and cardiovascular diseases. Saudi Med. J. 2010; 31: 486-489 PubMed Google Scholar ]. Hence, inhibition of HMGB1 might have therapeutic potential in the treatment of these diseases. As a supplement for Wang's research, we briefly introduced the role of HMGB1 in atherosclerosis and proposed that HMGB1 would be a promising therapeutic approach for atherosclerosis [ [3] de Souza A.W. Westra J. Limburg P.C. et al. HMGB1 in vascular diseases: Its role in vascular inflammation and atherosclerosis. Autoimmun. Rev. 2012; 11: 909-917 Crossref PubMed Scopus (106) Google Scholar ].
What problem does this paper attempt to address?